个人中心 - 老虎社区

JJSLIN

IP属地：未知

帖子 · 9帖子 · 9
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- JJSLINJJSLIN
  ·2021-12-10
  🚀🚀🚀
  OCGN Stock Pops on Key FDA News. Here’s What to Know.
  Biopharmaceutical company Ocugen(NASDAQ:OCGN) announced today that the U.S. Food and Drug Administra
  OCGN Stock Pops on Key FDA News. Here’s What to Know.
  904 评论
  4
  分享
  举报
- JJSLINJJSLIN
  ·2021-12-01
  $Histogenics(OCGN)$🚀🚀🚀
  639 评论
  5
  分享
  举报
- JJSLINJJSLIN
  ·2021-11-29
  End day become infinity 😀
  @JuanJohnson：
  Imagine now you would have to take 4 booster shots a year for life. Two for delta, two for omicron... And guess what? Next year you can add 4 more for another two variants that come along!Covaxin is good for all corona virus'$Histogenics(OCGN)$
  Imagine now you would have to take 4 booster shots a year for life. Two for delta, two for omicron... And guess what? Next year you can add 4 more for another two variants that come along!Covaxin is good for all corona virus'$Histogenics(OCGN)$
  610 评论
  点赞
  分享
  举报
- JJSLINJJSLIN
  ·2021-11-26
  $Histogenics(OCGN)$🚀🌙 💎🙌💎
  396 评论
  2
  分享
  举报
- JJSLINJJSLIN
  ·2021-11-08
  $Histogenics(OCGN)$Drop till I no feeling already.The best you can drop till $1 & let’s us ready for this roller coaster ride 🚀🚀🚀🚀🚀🚀
  1,318 1
  3
  分享
  举报
- JJSLINJJSLIN
  ·2021-05-24
  $Grayscale Ethereum Trust(ETHE)$Show Us Your Miracle
  814 2
  7
  分享
  举报
- JJSLINJJSLIN
  ·2021-04-30
  Thanks
  非常抱歉，此主贴已删除
  345 评论
  点赞
  分享
  举报
- JJSLINJJSLIN
  ·2021-04-16
  Let's earn more money
  GameStop’s Shakeup Will Do Little to Alleviate Its Woes
  GME stock's new leadership needs to get its priorities straight if it hopes to turn things around.Ga
  GameStop’s Shakeup Will Do Little to Alleviate Its Woes
  534 评论
  点赞
  分享
  举报
- JJSLINJJSLIN
  ·2021-04-16
  3.51
  非常抱歉，此主贴已删除
  405 评论
  点赞
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3581601922547073","uuid":"3581601922547073","gmtCreate":1618515768783,"gmtModify":1619755314114,"name":"JJSLIN","pinyin":"jjslin","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/bcd611a21236602bc49267fe3296259e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":18,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.78%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.08%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":605921011,"gmtCreate":1639103141916,"gmtModify":1639103141916,"author":{"id":"3581601922547073","authorId":"3581601922547073","name":"JJSLIN","avatar":"https://static.tigerbbs.com/bcd611a21236602bc49267fe3296259e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581601922547073","authorIdStr":"3581601922547073"},"themes":[],"htmlText":"🚀🚀🚀","listText":"🚀🚀🚀","text":"🚀🚀🚀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605921011","repostId":"1186120067","repostType":2,"repost":{"id":"1186120067","kind":"news","pubTimestamp":1639102922,"share":"https://www.laohunote.com/m/news/1186120067?lang=&edition=full","pubTime":"2021-12-10 10:22","market":"us","language":"en","title":"OCGN Stock Pops on Key FDA News. Here’s What to Know.","url":"https://stock-news.laohu8.com/highlight/detail?id=1186120067","media":"InvestorPlace","summary":"Biopharmaceutical company Ocugen(NASDAQ:OCGN) announced today that the U.S. Food and Drug Administra","content":"<p>Biopharmaceutical company&nbsp;<b>Ocugen</b>(NASDAQ:<b><u>OCGN</u></b>) announced today that the U.S. Food and Drug Administration (FDA) approved the company’s Investigational New Drug (IND) application for a human clinical trial of OCU400. OCU400 is a gene-therapy candidate targeting several degenerative eye diseases that severely impair vision. Despite the news, OCGN stock is down 6.3% today as investors seem reluctant to buy into the struggling med-tech company.</p>\n<p>Shankar Musunuri, chief executive and co-founder of Ocugen, commented on&nbsp;the significance of this recent development.</p>\n<blockquote>\n <i>“We are delighted to advance OCU400 into clinical trials, which exemplifies our goal of offering new options to people with genetic diseases where none currently exist. … We’re collaborating with leading centers in eye care and have been vital partners to getting our trial launched and receive patients. With this final decision by the FDA, we are embarking on a new pathway of care through this innovative gene therapy.”</i>\n</blockquote>\n<p>The news comes as a welcome change of pace for the company. Ocugen is perhaps best known for its Covid-19 vaccine Covaxin, which largely lags behind the competition. On Nov. 30, the FDA&nbsp;issued a hold&nbsp;on an approval application for late-stage clinical testing of its vaccine.</p>\n<p>Ocugen represents just the North American side of the vaccine’s distribution. Meanwhile,&nbsp;<b>Bharat Biotech</b>, co-developer of the vaccine, has earned approval for use in 17 countries, including the company’s native India. This stands in stark contrast to Ocugen, who many investors believe is&nbsp;too little too late. Ocugen has come under fire for attempting to penetrate largely saturated Western markets as it pertains to vaccine options.</p>\n<p>Will this latest news shake things up for the struggling pharma company?</p>\n<p>OCU400: A Silver Lining for Struggling OCGN stock</p>\n<p>Arguably, OCU400 is Ocugen’s main prize-horse going forward. Anticipation surrounding the company’s breakthrough gene-therapy programs has taken OCGN stock to the moon and back in the past few years. However, that anticipation has largely died down. With many estimating it could be years before such a therapy hits the market, combined with seemingly constant roadblocks for its vaccine candidate, OCGN stock has been on a cold streak for quite a while. Therefore, this news should come as a breath of fresh air for OCGN investors.</p>\n<p>Preliminary estimates see OCU400 being a completely novel solution to a series of retinal degenerative diseases. This year, the European Medicines Agency (EMA) even granted OCU400 a broad medical designation&nbsp;for two different optical diseases.</p>\n<p>While investors currently seem hesitant, hope isn’t lost yet. Positive developments of this nature can create the positive momentum necessary to bring the stock back from the dead.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OCGN Stock Pops on Key FDA News. Here’s What to Know.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOCGN Stock Pops on Key FDA News. Here’s What to Know.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 10:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/ocgn-stock-pops-on-key-fda-news-heres-what-to-know/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biopharmaceutical company Ocugen(NASDAQ:OCGN) announced today that the U.S. Food and Drug Administration (FDA) approved the company’s Investigational New Drug (IND) application for a human clinical ...</p>\n\n<a href=\"https://investorplace.com/2021/12/ocgn-stock-pops-on-key-fda-news-heres-what-to-know/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/12/ocgn-stock-pops-on-key-fda-news-heres-what-to-know/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186120067","content_text":"Biopharmaceutical company Ocugen(NASDAQ:OCGN) announced today that the U.S. Food and Drug Administration (FDA) approved the company’s Investigational New Drug (IND) application for a human clinical trial of OCU400. OCU400 is a gene-therapy candidate targeting several degenerative eye diseases that severely impair vision. Despite the news, OCGN stock is down 6.3% today as investors seem reluctant to buy into the struggling med-tech company.\nShankar Musunuri, chief executive and co-founder of Ocugen, commented on the significance of this recent development.\n\n“We are delighted to advance OCU400 into clinical trials, which exemplifies our goal of offering new options to people with genetic diseases where none currently exist. … We’re collaborating with leading centers in eye care and have been vital partners to getting our trial launched and receive patients. With this final decision by the FDA, we are embarking on a new pathway of care through this innovative gene therapy.”\n\nThe news comes as a welcome change of pace for the company. Ocugen is perhaps best known for its Covid-19 vaccine Covaxin, which largely lags behind the competition. On Nov. 30, the FDA issued a hold on an approval application for late-stage clinical testing of its vaccine.\nOcugen represents just the North American side of the vaccine’s distribution. Meanwhile, Bharat Biotech, co-developer of the vaccine, has earned approval for use in 17 countries, including the company’s native India. This stands in stark contrast to Ocugen, who many investors believe is too little too late. Ocugen has come under fire for attempting to penetrate largely saturated Western markets as it pertains to vaccine options.\nWill this latest news shake things up for the struggling pharma company?\nOCU400: A Silver Lining for Struggling OCGN stock\nArguably, OCU400 is Ocugen’s main prize-horse going forward. Anticipation surrounding the company’s breakthrough gene-therapy programs has taken OCGN stock to the moon and back in the past few years. However, that anticipation has largely died down. With many estimating it could be years before such a therapy hits the market, combined with seemingly constant roadblocks for its vaccine candidate, OCGN stock has been on a cold streak for quite a while. Therefore, this news should come as a breath of fresh air for OCGN investors.\nPreliminary estimates see OCU400 being a completely novel solution to a series of retinal degenerative diseases. This year, the European Medicines Agency (EMA) even granted OCU400 a broad medical designation for two different optical diseases.\nWhile investors currently seem hesitant, hope isn’t lost yet. Positive developments of this nature can create the positive momentum necessary to bring the stock back from the dead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":904,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603113779,"gmtCreate":1638372713520,"gmtModify":1638372713685,"author":{"id":"3581601922547073","authorId":"3581601922547073","name":"JJSLIN","avatar":"https://static.tigerbbs.com/bcd611a21236602bc49267fe3296259e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581601922547073","authorIdStr":"3581601922547073"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>🚀🚀🚀","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>🚀🚀🚀","text":"$Histogenics(OCGN)$🚀🚀🚀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603113779","isVote":1,"tweetType":1,"viewCount":639,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600429819,"gmtCreate":1638190098563,"gmtModify":1638190098719,"author":{"id":"3581601922547073","authorId":"3581601922547073","name":"JJSLIN","avatar":"https://static.tigerbbs.com/bcd611a21236602bc49267fe3296259e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581601922547073","authorIdStr":"3581601922547073"},"themes":[],"htmlText":"End day become&nbsp;infinity 😀","listText":"End day become&nbsp;infinity 😀","text":"End day become infinity 😀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600429819","repostId":"600463556","repostType":1,"repost":{"id":600463556,"gmtCreate":1638189041072,"gmtModify":1638189041072,"author":{"id":"9000000000000198","authorId":"9000000000000198","name":"JuanJohnson","avatar":"https://static.tigerbbs.com/11f0390f4344fa15e794478b64ee460f","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"9000000000000198","authorIdStr":"9000000000000198"},"themes":[],"htmlText":"Imagine now you would have to take 4 booster shots a year for life. Two for delta, two for omicron... And guess what? Next year you can add 4 more for another two variants that come along!Covaxin is good for all corona virus'<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>","listText":"Imagine now you would have to take 4 booster shots a year for life. Two for delta, two for omicron... And guess what? Next year you can add 4 more for another two variants that come along!Covaxin is good for all corona virus'<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>","text":"Imagine now you would have to take 4 booster shots a year for life. Two for delta, two for omicron... And guess what? Next year you can add 4 more for another two variants that come along!Covaxin is good for all corona virus'$Histogenics(OCGN)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600463556","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":610,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877605122,"gmtCreate":1637919833671,"gmtModify":1637919833721,"author":{"id":"3581601922547073","authorId":"3581601922547073","name":"JJSLIN","avatar":"https://static.tigerbbs.com/bcd611a21236602bc49267fe3296259e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581601922547073","authorIdStr":"3581601922547073"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>🚀🌙 💎🙌💎","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>🚀🌙 💎🙌💎","text":"$Histogenics(OCGN)$🚀🌙 💎🙌💎","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877605122","isVote":1,"tweetType":1,"viewCount":396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844946450,"gmtCreate":1636385029144,"gmtModify":1636385041175,"author":{"id":"3581601922547073","authorId":"3581601922547073","name":"JJSLIN","avatar":"https://static.tigerbbs.com/bcd611a21236602bc49267fe3296259e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581601922547073","authorIdStr":"3581601922547073"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Drop till I no feeling already.The best you can drop till $1 &amp; let’s us ready for &nbsp; &nbsp;this roller coaster ride 🚀🚀🚀🚀🚀🚀","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Drop till I no feeling already.The best you can drop till $1 &amp; let’s us ready for &nbsp; &nbsp;this roller coaster ride 🚀🚀🚀🚀🚀🚀","text":"$Histogenics(OCGN)$Drop till I no feeling already.The best you can drop till $1 & let’s us ready for this roller coaster ride 🚀🚀🚀🚀🚀🚀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/844946450","isVote":1,"tweetType":1,"viewCount":1318,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":131408582,"gmtCreate":1621870841346,"gmtModify":1631889372722,"author":{"id":"3581601922547073","authorId":"3581601922547073","name":"JJSLIN","avatar":"https://static.tigerbbs.com/bcd611a21236602bc49267fe3296259e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581601922547073","authorIdStr":"3581601922547073"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ETHE\">$Grayscale Ethereum Trust(ETHE)$</a>Show Us Your Miracle","listText":"<a href=\"https://laohu8.com/S/ETHE\">$Grayscale Ethereum Trust(ETHE)$</a>Show Us Your Miracle","text":"$Grayscale Ethereum Trust(ETHE)$Show Us Your Miracle","images":[{"img":"https://static.tigerbbs.com/a8618146c60ff323395f52e7692be4c2","width":"1440","height":"3200"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/131408582","isVote":1,"tweetType":1,"viewCount":814,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":103934635,"gmtCreate":1619742458927,"gmtModify":1634210294637,"author":{"id":"3581601922547073","authorId":"3581601922547073","name":"JJSLIN","avatar":"https://static.tigerbbs.com/bcd611a21236602bc49267fe3296259e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581601922547073","authorIdStr":"3581601922547073"},"themes":[],"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/103934635","repostId":"2131534297","repostType":4,"isVote":1,"tweetType":1,"viewCount":345,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":347437100,"gmtCreate":1618516395800,"gmtModify":1634292419920,"author":{"id":"3581601922547073","authorId":"3581601922547073","name":"JJSLIN","avatar":"https://static.tigerbbs.com/bcd611a21236602bc49267fe3296259e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581601922547073","authorIdStr":"3581601922547073"},"themes":[],"htmlText":"Let's earn more money&nbsp;","listText":"Let's earn more money&nbsp;","text":"Let's earn more money","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/347437100","repostId":"1153108819","repostType":4,"repost":{"id":"1153108819","kind":"news","pubTimestamp":1618497574,"share":"https://www.laohunote.com/m/news/1153108819?lang=&edition=full","pubTime":"2021-04-15 22:39","market":"us","language":"en","title":"GameStop’s Shakeup Will Do Little to Alleviate Its Woes","url":"https://stock-news.laohu8.com/highlight/detail?id=1153108819","media":"InvestorPlace","summary":"GME stock's new leadership needs to get its priorities straight if it hopes to turn things around.Ga","content":"<blockquote>GME stock's new leadership needs to get its priorities straight if it hopes to turn things around.</blockquote><p>GameStoop fell about 7.5%&nbsp;in morning  trading.</p><p><img src=\"https://static.tigerbbs.com/48ede96d6233c7b39a789ae18b488344\" tg-width=\"708\" tg-height=\"500\" referrerpolicy=\"no-referrer\"></p><p>Video game retailer&nbsp;<b>GameStop</b>(NYSE:<b><u>GME</u></b>) is the most talked-about meme stock in recent memory. Thanks to a Reddit-induced short squeeze, it is one of the best-performing stocks in the past 12 months, with hardly any fundamentals to back that up. Despite a 40% drop in its price this month, it still trades more than 89 times its cash flows. What’s next for GME stock is anybody’s guess, but one thing is clear: the odds are heavily stacked against Gamestop in transforming its business.</p><p>A lot is riding on the induction ofChewy co-founder Ryan Cohenfor the company’s big e-commerce pivot. Under Cohen, the newly revamped board of directors is transforming the company from a retailer to a technology company. Global E-commerce saleshave shot up 191% in fiscal 2020, which shows its initiatives’ potential. However, nothing is a given with GameStop, considering its spotty track record. There are many holes in the company’s strategic plans, which should continue to impact its long-term outlook.</p><p><b>Cohen’s Transformative Plans</b></p><p>In an executive shakeup, GameStop named Ryan Cohen as its chairman. Cohen is known as an activist investor and the co-founder of pet supplies retailer Chewy.&nbsp; Hehad purchased a 10% stakein GameStop back in August last year and later increased it to 13%. In an SEC feeling in November, he talked about how the company needed to transform itself from a retailer to a tech company.</p><p>Naturally, Cohen has brought new leadership in executing his plans. However, to everyone’s surprise, the new appointments include marketers, customer care experts, web designers, and other IT professionals with little hands-on knowledge in the gaming industry. One would expect Cohen to introduce individuals with practical experience of the industry and well-versed with its developments.</p><p>More importantly, he seems to be missing the plot about how GameStop’s competition is incidentally its vendors. With the rising popularity of digital purchases, original equipment manufacturers (OEMs) are becoming less reliant on intermediary businesses. &nbsp;Therefore in many ways, the latest console upgrade cycle is likely to be significantly less profitable.</p><p>The last console upgrade cycle was back in 2013, where total global sales for its holiday periodwere at $3.15 billion. On the flip side, the holiday results for 2020 were at $1.7 billion, whichdecreased 3.1% compared to 2019. Hence, OEMs will continue to offer their content through their digital platforms, limiting GameStop and other related companies’ market share.</p><p><b>The Bottom Line on GME Stock</b></p><p>So where will the company go from here? I have no idea. The GameStop saga has arguably been one of the weirdest stock market stories in recent memory. It’s clear from a fundamental standpoint, though, that the stock is grossly overvalued.&nbsp; For example, its enterprise value to EBITDA ratio is more than 3,600% higher than the sector average. Moreover, its forward price to book ratio is also more than 375% higher than the sector average.</p><p>Many price targets for the stock are more than 70% lower than its current stock price. Moreover, the dispersal between its high and low estimates is more than $150 at this time. The reality is that if you factor in the risks associated with its business, its value is not even close to where it’s trading at this time.</p><p>GME stock has had a rollercoaster of a ride this year. However, it appears that it’s not exactly the mother of all short stocks at this point. Short interest as a % of the float was roughly 18% when it exceeded 100% in January. Moreover, its new chairman in Ryan Cohen seems to be missing the trick in understanding the company’s underlying problems. Therefore, it would be best for long and short sellers to steer clear of GME Stock.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GameStop’s Shakeup Will Do Little to Alleviate Its Woes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGameStop’s Shakeup Will Do Little to Alleviate Its Woes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 22:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/04/gme-stock-shakeup-will-do-little-to-alleviate-its-woes/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GME stock's new leadership needs to get its priorities straight if it hopes to turn things around.GameStoop fell about 7.5% in morning  trading.Video game retailer GameStop(NYSE:GME) is the most ...</p>\n\n<a href=\"https://investorplace.com/2021/04/gme-stock-shakeup-will-do-little-to-alleviate-its-woes/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站"},"source_url":"https://investorplace.com/2021/04/gme-stock-shakeup-will-do-little-to-alleviate-its-woes/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153108819","content_text":"GME stock's new leadership needs to get its priorities straight if it hopes to turn things around.GameStoop fell about 7.5% in morning  trading.Video game retailer GameStop(NYSE:GME) is the most talked-about meme stock in recent memory. Thanks to a Reddit-induced short squeeze, it is one of the best-performing stocks in the past 12 months, with hardly any fundamentals to back that up. Despite a 40% drop in its price this month, it still trades more than 89 times its cash flows. What’s next for GME stock is anybody’s guess, but one thing is clear: the odds are heavily stacked against Gamestop in transforming its business.A lot is riding on the induction ofChewy co-founder Ryan Cohenfor the company’s big e-commerce pivot. Under Cohen, the newly revamped board of directors is transforming the company from a retailer to a technology company. Global E-commerce saleshave shot up 191% in fiscal 2020, which shows its initiatives’ potential. However, nothing is a given with GameStop, considering its spotty track record. There are many holes in the company’s strategic plans, which should continue to impact its long-term outlook.Cohen’s Transformative PlansIn an executive shakeup, GameStop named Ryan Cohen as its chairman. Cohen is known as an activist investor and the co-founder of pet supplies retailer Chewy.  Hehad purchased a 10% stakein GameStop back in August last year and later increased it to 13%. In an SEC feeling in November, he talked about how the company needed to transform itself from a retailer to a tech company.Naturally, Cohen has brought new leadership in executing his plans. However, to everyone’s surprise, the new appointments include marketers, customer care experts, web designers, and other IT professionals with little hands-on knowledge in the gaming industry. One would expect Cohen to introduce individuals with practical experience of the industry and well-versed with its developments.More importantly, he seems to be missing the plot about how GameStop’s competition is incidentally its vendors. With the rising popularity of digital purchases, original equipment manufacturers (OEMs) are becoming less reliant on intermediary businesses.  Therefore in many ways, the latest console upgrade cycle is likely to be significantly less profitable.The last console upgrade cycle was back in 2013, where total global sales for its holiday periodwere at $3.15 billion. On the flip side, the holiday results for 2020 were at $1.7 billion, whichdecreased 3.1% compared to 2019. Hence, OEMs will continue to offer their content through their digital platforms, limiting GameStop and other related companies’ market share.The Bottom Line on GME StockSo where will the company go from here? I have no idea. The GameStop saga has arguably been one of the weirdest stock market stories in recent memory. It’s clear from a fundamental standpoint, though, that the stock is grossly overvalued.  For example, its enterprise value to EBITDA ratio is more than 3,600% higher than the sector average. Moreover, its forward price to book ratio is also more than 375% higher than the sector average.Many price targets for the stock are more than 70% lower than its current stock price. Moreover, the dispersal between its high and low estimates is more than $150 at this time. The reality is that if you factor in the risks associated with its business, its value is not even close to where it’s trading at this time.GME stock has had a rollercoaster of a ride this year. However, it appears that it’s not exactly the mother of all short stocks at this point. Short interest as a % of the float was roughly 18% when it exceeded 100% in January. Moreover, its new chairman in Ryan Cohen seems to be missing the trick in understanding the company’s underlying problems. Therefore, it would be best for long and short sellers to steer clear of GME Stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":534,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":347434748,"gmtCreate":1618516292784,"gmtModify":1634292420141,"author":{"id":"3581601922547073","authorId":"3581601922547073","name":"JJSLIN","avatar":"https://static.tigerbbs.com/bcd611a21236602bc49267fe3296259e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581601922547073","authorIdStr":"3581601922547073"},"themes":[],"htmlText":"3.51","listText":"3.51","text":"3.51","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/347434748","repostId":"1181372898","repostType":4,"isVote":1,"tweetType":1,"viewCount":405,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":false}